Otto G, Braconier J, Andreasson A, Svanborg C
Department of Medical Microbiology, Division of Clinical Immunology, Lund University, Sweden.
J Infect Dis. 1999 Jan;179(1):172-9. doi: 10.1086/314534.
An interleukin-6 (IL-6) response was detected in 81 patients with febrile urinary tract infections (UTIs). Bacteremic patients (n=24) had higher serum IL-6 at inclusion and throughout the first 24 h (P<. 01) and higher urine IL-6 from 6 h after start of therapy (P<.01) than did nonbacteremic patients (n=57). The serum and urine IL-6 responses remained elevated longer in the bacteremic group. Patients with clinical signs of pyelonephritis had higher serum and urine IL-6 concentrations than did other patients in the study population (P=.058, P<.01, respectively). IL-6 high responders had higher temperatures (P<.05) and C-reactive protein levels (P<.05, P<.01) than did low responders. The results demonstrate that IL-6 responses accompany febrile UTIs regardless of bacteremia and that the response reflects disease severity. The results suggest that IL-6 produced in the urinary tract can trigger the systemic host response in the absence of bacteremia.
在81例发热性尿路感染(UTI)患者中检测到白细胞介素-6(IL-6)反应。与非菌血症患者(n = 57)相比,菌血症患者(n = 24)在纳入时及最初24小时内血清IL-6水平更高(P < 0.01),且从治疗开始6小时后尿IL-6水平更高(P < 0.01)。菌血症组血清和尿IL-6反应持续升高的时间更长。肾盂肾炎临床体征患者的血清和尿IL-6浓度高于研究人群中的其他患者(分别为P = 0.058,P < 0.01)。IL-6高反应者比低反应者体温更高(P < 0.05),C反应蛋白水平更高(P < 0.05,P < 0.01)。结果表明,无论是否存在菌血症,IL-6反应都伴随发热性UTI,且该反应反映疾病严重程度。结果提示,在无菌血症的情况下,尿路中产生的IL-6可触发全身宿主反应。